• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Lärkberget

2.26 SEK-2.16 %13.8. klo 18.29
Less than 1K followers

LARK

First North Stockholm

Investment

Financials

Overview
Financials & Estimates
Ownership
Dividend
Compare
-2.16 %
-1.74 %
+2.73 %
-3.83 %
0.00 %
-4.64 %
-66.91 %
-71.96 %
-97.64 %

Lärkberget is a Swedish investment company. The company's main areas of activity are direct investments in low-risk instruments, investments in listed shares, funds and other liquid asset classes, as well as participation in bridge loans and guarantee commitments, investments in unlisted profitable companies, and reverse acquisitions. Lärkberget is headquartered in Stockholm.

Read more
Market cap
44.75M SEK
Turnover
2.65K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.8.
2026

Interim report Q2'26

11.2.
2027

Annual report '26

All
Press releases
3rd party
ShowingAll content types

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Third party research14.02.2025 klo 12.01

CombiGene: Making place for new ventures - VH Corp

• All research activities discontinued • Notice of an extraordinary general meeting on February 20, 2025 • Q&A with chairman Luca Di Stefano After a strategic evaluation of its operations, CombiGene’s board decided to discontinue all research activities...

Lärkberget
Press release14.02.2025 klo 10.21

Västra Hamnen Market Focus: CombiGene: Making place for new ventures

Lärkberget
Regulatory press release14.02.2025 klo 09.50

Year-end report January-December 2024 CombiGene AB (Publ)

Lärkberget

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release28.01.2025 klo 09.30

Discontinuation of research activities

Lärkberget
Regulatory press release09.01.2025 klo 17.00

Stockslätten AB acquires all shares from Strategic Partners A/S

Lärkberget
Regulatory press release09.01.2025 klo 16.50

Clarification regarding the management's role during the restructuring period

Lärkberget
Regulatory press release09.01.2025 klo 09.45

CombiGene initiates restructuring as part of strategic review to maximize shareholder value

Lärkberget
Regulatory press release17.12.2024 klo 15.30

CombiGene AB (publ): Nominating committee

Lärkberget
Regulatory press release10.12.2024 klo 15.50

Bulletin from the Extraordinary General Meeting of CombiGene AB (publ)

Lärkberget
Press release02.12.2024 klo 16.00

CombiGene conducts Extraordinary General Meeting

Lärkberget
Regulatory press release14.11.2024 klo 16.40

Shareholders’ proposal for election of Board of Directors

Lärkberget
Third party research11.11.2024 klo 15.39

CombiGene: Strategic consequences after CG01 - VH Corp

* Implementing cost savings and new priorities * New propositions from the main shareholder * Our revised fair value estimate is SEK 8.27 (12.19) per share In our previous analysis, CombiGene was focused on outlicensing the epilepsy project CG01 again...

Lärkberget
Regulatory press release08.11.2024 klo 10.00

Interim report January – September 2024 for CombiGene AB (publ)

Lärkberget
Regulatory press release01.11.2024 klo 11.00

NOTICE OF EXTRAORDINARY GENERAL MEETING IN COMBIGENE AB (PUBL)

Lärkberget
Regulatory press release31.10.2024 klo 19.00

The Board of Directors of CombiGene has received proposals from the Company’s largest shareholder for the Extraordinary General Meeting intended to be convened

Lärkberget
Press release30.10.2024 klo 10.07

BioStock: CombiGene implements cost savings

Lärkberget
Third party research30.10.2024 klo 08.21

CombiGene: New priorities after strategic decision - VH Corp

* Terminating the CG01 programme * Implementing cost savings to prolong the financial runway * Our fair value estimate is under review Recently, CombiGene announced new priorities in its pipeline and a cost saving programme to prolong its financial runway...

Lärkberget
Press release29.10.2024 klo 17.15

Västra Hamnen Market Focus: CombiGene: New priorities after strategic decision

Lärkberget
Regulatory press release28.10.2024 klo 09.50

CombiGene Initiates Measures to Extend Liquidity Horizon by Sharpening Strategic Focus on Gene Therapy, Prioritizing Pipeline Assets, and Implementing a Cost Reduction Program

Lärkberget
Regulatory press release30.09.2024 klo 14.15

CombiGene announces new preclinical research results in the epilepsy project

Lärkberget